日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial

一种由人工智能发现的用于治疗特发性肺纤维化的TNIK抑制剂:一项随机2a期试验

Xu, Zuojun; Ren, Feng; Wang, Ping; Cao, Jie; Tan, Chunting; Ma, Dedong; Zhao, Li; Dai, Jinghong; Ding, Yipeng; Fang, Haohui; Li, Huiping; Liu, Hong; Luo, Fengming; Meng, Ying; Pan, Pinhua; Xiang, Pingchao; Xiao, Zuke; Rao, Sujata; Satler, Carol; Liu, Sang; Lv, Yuan; Zhao, Heng; Chen, Shan; Cui, Hui; Korzinkin, Mikhail; Gennert, David; Zhavoronkov, Alex

Dual PDE4/10A inhibition restores CREB1 function and enhances neuronal resilience in models of alzheimer's disease.

双重 PDE4/10A 抑制可恢复 CREB1 功能,并增强阿尔茨海默病模型中的神经元恢复力。

Rong Xiaoli, Yao Xia, Fang Haohui, Saji Johns, Qian Yu, Gu Jia-Xuan, Yang Meng-Yuan, Wei Peng, Liu Cai-Rui, Chen Bin, Zhao Pian-Pian, Cheung Ching-Lung, Bo Lin, Zheng Hou-Feng

Dupilumab Efficacy and Safety in Patients With Persistent Asthma: Asia-Pacific Region

Dupilumab治疗持续性哮喘患者的疗效和安全性:亚太地区

Zhang, Qingling; Zhong, Nanshan; Dhooria, Sahajal; Fu, Xiuhua; Fang, Haohui; Lin, Jie; Zhu, Shuyang; Laws, Elizabeth; Wang, Yi; Li, Vivian; Hu, Chih-Chi; Maloney, Jennifer; Abdulai, Raolat M; Robinson, Lacey B

APOE genotype confers context-dependent neurovascular vulnerability in immune-vascularized human forebrain organoids.

APOE 基因型赋予免疫血管化的人类前脑类器官依赖于环境的神经血管脆弱性

Fang Haohui, Liao Xiangyu, Bullen C Korin, Pu Ruoyan, Wang Hu, Condoleo Juliana, Chear Sueanne, Chen Xueyi, Zhang Yanjun, Zhang Sonya, Huo Da, Lissit Kadia, Yang Alina, Jarvis Kateri, Neifert Stewart, Huang Yuejia, Bishai William, Jain Sanjay K, Dawson Ted M, Dawson Valina L, Xu Jin-Chong

Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial

Benmelstobart、安罗替尼和化疗治疗广泛期小细胞肺癌:一项随机3期试验

Cheng, Ying; Chen, Jianhua; Zhang, Wei; Xie, Chao; Hu, Qun; Zhou, Ningning; Huang, Chun; Wei, Shihong; Sun, Hong; Li, Xingya; Yu, Yan; Lai, Jinhuo; Yang, Huaping; Fang, Haohui; Chen, Hualin; Zhang, Peng; Gu, Kangsheng; Wang, Qiming; Shi, Jianhua; Yi, Tienan; Xu, Xingxiang; Ye, Xianwei; Wang, Daqing; Xie, Conghua; Liu, Chunling; Zheng, Yulong; Lin, Daren; Zhuang, Wu; Lu, Ping; Yu, Guohua; Li, Jinzhang; Gu, Yuhai; Li, Baolan; Wu, Rong; Jiang, Ou; Wang, Zaiyi; Wu, Guowu; Lin, Haifeng; Zhong, Diansheng; Xu, Yanhua; Shu, Yongqian; Wu, Di; Chen, Xingwu; Wang, Jie; Wang, Minghui; Yang, Runxiang

Corrigendum: Advanced NSCLC patients with EGFR T790M harbouring TP53 R273C or KRAS G12V cannot benefit from osimertinib based on a clinical multicentre study by tissue and liquid biopsy

更正:根据一项通过组织和液体活检进行的临床多中心研究,携带 TP53 R273C 或 KRAS G12V 突变的 EGFR T790M 晚期 NSCLC 患者无法从奥希替尼治疗中获益。

Fu, Yulong; Wang, Anqi; Zhou, Jieqi; Feng, Wei; Shi, Minhua; Xu, Xiao; Zhao, Hongqing; Cai, Liming; Feng, Jian; Lv, Xuedong; Zhang, Xiaodong; Xu, Wenjing; Zhang, Zhengrong; Ma, Guoer; Wang, Jian; Zhou, Tong; Zhao, Dahai; Fang, Haohui; Liu, Zeyi; Huang, Jian-An

Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind study

MIL60 与贝伐单抗治疗晚期或复发性非鳞状非小细胞肺癌的疗效和安全性比较:一项 3 期随机双盲研究

Wan, Rui; Dong, Xiaorong; Chen, Qun; Yu, Yan; Yang, Shujun; Zhang, Xiaochun; Zhang, Guojun; Pan, Yueyin; Sun, Sanyuan; Zhou, Chengzhi; Hong, Wei; Zhao, Hui; Yang, Lei; Huang, Linian; Wu, Rong; Zang, Aimin; Ma, Rui; Wu, Lin; Lv, Dongqing; Fu, Xiuhua; Han, Jianguo; Li, Wenxin; Duan, Jianchun; Wang, Kai; Jiang, Ou; Chen, Yinglan; Guo, Zhongliang; Gao, Hongjun; Wen, Juyi; Wang, Shubin; Zhao, Enfeng; Li, Gaofeng; Yue, Lu; Liang, Li; Zeng, Aiping; Wang, Xiaoshan; Zhu, Yuxi; Pan, Hongming; Dai, Zhaoxia; Feng, Weineng; Zhao, Guofang; Lin, Chuan; Li, Chong; Li, Na; Bao, Yangyi; Li, Yinyin; Su, Yanjun; Zhao, Min; Fang, Haohui; Zhu, Yulong; Zhang, Yu; Ding, Lieming; Wang, Yang; Yuan, Xiaobin; Wang, Jie

Advanced NSCLC Patients With EGFR T790M Harboring TP53 R273C or KRAS G12V Cannot Benefit From Osimertinib Based on a Clinical Multicentre Study by Tissue and Liquid Biopsy

根据一项基于组织和液体活检的多中心临床研究,携带 TP53 R273C 或 KRAS G12V 突变的 EGFR T790M 晚期非小细胞肺癌患者无法从奥希替尼治疗中获益。

Fu, Yulong; Wang, Anqi; Zhou, Jieqi; Feng, Wei; Shi, Minhua; Xu, Xiao; Zhao, Hongqing; Cai, Liming; Feng, Jian; Lv, Xuedong; Zhang, Xiaodong; Xu, Wenjing; Zhang, Zhengrong; Ma, Guoer; Wang, Jian; Zhou, Tong; Zhao, Dahai; Fang, Haohui; Liu, Zeyi; Huang, Jian-An